March 9 (Reuters) – Vertex Pharmaceuticals said on Monday that its experimental kidney disease drug met the main goal of a late-stage trial.
Shares of the company were up about 10% in extended trading.
Vertex was testing the drug, povetacicept, in patients with IgA nephropathy, a serious autoimmune disease that can lead to kidney failure or death in a large proportion of patients within 20 years of diagnosis, according to the company.
Patients who received the drug saw protein leakage in their urine fall by 52% after 36 weeks, compared with a 4.3% drop in the placebo group.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Sahal Muhammed)
Comments